Evidence map›Paper›PMID 33003523›Full record

ArticleJournal of clinical medicine2020

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction.

Daniele Masarone, Vittoria Errigo, Enrico Melillo, Fabio Valente, Rita Gravino, Marina Verrengia, Ernesto Ammendola, Rossella Vastarella, Giuseppe Pacileo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Daniele MasaroneHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Vittoria ErrigoHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Enrico MelilloHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Fabio ValenteHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Rita GravinoHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Marina VerrengiaHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Ernesto AmmendolaHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Rossella VastarellaHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Giuseppe PacileoHeart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, 80121 Naples, Italy.
Ospedale Monaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundright ventricle-pulmonary artery (RV-PA) coupling assessed by measuring the tricuspid anular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio has been recently proposed as an early marker of right ventricular dysfunction in patients with heart failure with a reduced ejection fraction (HFrEF).

methodsAs the effects of sacubitril/valsartan therapy on RV-PA coupling remain unknown, this study aimed to analyse the effect of this drug on TAPSE/PASP in patients with HFrEF. We retrospectively analysed all outpatients with HFrEF referred to our unit between October 2016 and July 2018.

resultsAt the 1-year follow-up, sacubitril/valsartan therapy was associated with a significant improvement in TAPSE (18.26 ± 3.7 vs. 19.6 ± 4.2 mm,

conclusionsin patients with HFrEF, sacubitril/valsartan improved the RV-PA coupling; however, further trials are necessary to evaluate the role of sacubitril/valsartan in the treatment of right ventricle (RV) dysfunction either associated or not associated with left ventricular dysfunction.

Indexed as

heart failure reduced ejection fractionright ventricleright ventricular arterial couplingsacubitril/valsartan

Identifiers

PMID33003523
PMCPMC7600827
OpenAlexW3090345337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.